Envestnet Asset Management
KROS icon

Envestnet Asset Management’s Keros Therapeutics KROS Stock Holding History

Envestnet Asset Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,798
Closed -$251K – 4242
2024
Q1 		$251K Buy
+3,798
New +$225K ﹤0.01% 3821

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Envestnet Asset Management's KROS Position: Q2 2024 in Review

Envestnet Asset Management sold out of Keros Therapeutics (KROS) in Q2 2024, closing a stake of 3,798 shares — an estimated $251K sold.

Envestnet Asset Management first reported a position in KROS in Q1 2024 and held it in 1 quarter. The position peaked at $251K in Q1 2024. 152 funds tracked by Wall St. Rank hold KROS as of Q2 2024.

  • Envestnet Asset Management reported no remaining Keros Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Envestnet Asset Management sold 3,798 Keros Therapeutics shares in Q2 2024, an estimated $251K.
  • Envestnet Asset Management first reported a position in Keros Therapeutics in Q1 2024 and held it in 1 quarter.
  • Envestnet Asset Management's Keros Therapeutics position peaked at $251K in Q1 2024.
  • 152 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2024.

Based on Envestnet Asset Management's 13F filing for Q2 2024, filed 8 Aug 2024.